Alzheimer's Disease Competitive Intelligence: March 31, 2026

Mar 16, 2026 – Mar 31, 2026

Seven events across seven companies defined the second half of March 2026, spanning all four event categories. Anavex withdrew its EU marketing authorization application for blarcamesine in early AD after the EMA CHMP indicated it could not issue a positive opinion. NeuroSense rescheduled its Health Canada pre-NDS meeting to May 2026 to strengthen the PrimeC regulatory package and signaled a near-term AD clinical readout. NKGen Biotech reported Phase 1 troculeucel data showing dose-responsive cognitive improvements in moderate AD at AD/PD 2026. Annovis Bio presented a Phase 3 enrollment update for buntanetap at AD/PD 2026 (760 participants, 83 US sites, dual 6- and 18-month readouts). ProMIS Neurosciences completed PRECISE-AD enrollment at 144 participants with DSMB clearance to the highest dose cohort and Q3 2026 blinded data expected. Acumen Pharmaceuticals closed a $35.75M RA Capital-led private placement to advance its TfR-targeting EBD program for AD. Lunai Bioworks acquired a prodrug BBB delivery platform from the Clemann Group for $20M in Series B Convertible Preferred.